ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Challenging esophageal surgery: risk factors, outcomes, and a comparative single-center analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEsophageal cancer ranks as the eighth most common cancer among human populations and stands as the sixth leading cause of cancer-related deaths. Effective treatment of esophageal tumors necessitates a comprehensive, multidisciplinary approach encompassing surgery, chemotherapy, and radiotherapy.
methodIn our series of 203 esophagectomies conducted at our institution, we identified 28 procedures (13.7%) categorized as "challenging esophagectomies" based on specific predefined criteria outlined in the text. These criteria encompassed factors such as medical comorbidities, local tumor extension, and involvement of lymph nodes. The remaining 175 patients comprised the group of "standard esophagectomies".
resultsWe compared our study group with the standard group. There was no statistical difference between the two groups regarding overall 5 year survival and disease-free survival. In the "challenging esophagectomies" group, our overall 5 year survival rate was 34.2%, and the disease-free survival rate was 56, 4%. In the "standard" group, our overall 5 year survival rate was 48, 6%, and the disease-free survival rate was 58, 6%. Specifically, in the "challenging esophagectomies" group, the post-operative mortality rate stood at 8%, with major complications occurring in 33% of cases, in "standard group" the post-operative mortality rate stood at 2%, with major complications occurring in 23% of cases.
conclusionDespite the challenges associated with difficult esophagectomies, they play a pivotal role not only as salvage surgeries but also as a crucial component within the integrated multimodal treatment strategy. Patient selection emerges as a critical factor influencing outcomes. For this purpose, we propose a classification system of criteria and scores to define the level of complexity in this surgery.
Indexed as
Identifiers
41838349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.